Last reviewed · How we verify
Naropin
At a glance
| Generic name | Naropin |
|---|---|
| Also known as | Naropin, 0.5% Injectable Solution, ropivacaine |
| Sponsor | Taiwan Liposome Company |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | discontinued |
Approved indications
Common side effects
Key clinical trials
- Is Paraspinal Intramuscular Ropivacaine Injection an Effective Treatment for Headache in a Pediatric Emergency Department? (NA)
- Quadratus Lumborum Block Reduced Postpartum Uterine Pain After Virginal Childbirth (NA)
- A Randomized Controlled Comparison of PECI/SPB Versus Intercostal Nerve Block for the Management of Postoperative Pain in Latissimus Dorsi Flap Reconstruction (NA)
- Improving Pain and Function in Hip Fracture (Phase 3)
- Acute Pain in Hip Fracture Patients: Pain Management in the Emergency Department, a Mixed Method Study¨. Nurse Led Ultrasound Guided Femoral Nerve Block in the Emergency Department (NA)
- The Effect of Tramadol on Interscalene Brachial Plexus Block With Ropivacaine in Shoulder Surgery. (Phase 2)
- Effect of Erector Spinae Plane Block on Postoperative Pain in Patients With Breast Cancer Implant Reconstruction (NA)
- Perioperative Multimodal General AnesTHesia Focusing on Specific CNS Targets in Patients Undergoing carDiac surgERies - the PATHFINDER II Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Naropin CI brief — competitive landscape report
- Naropin updates RSS · CI watch RSS
- Taiwan Liposome Company portfolio CI